Second-generation chimeric antigen receptors (CARs) are powerful tools to redirect antigen-
specific T cells independently of HLA-restriction. Recent clinical studies evaluating CD19 …

Background Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and
is the most common lymphoid malignancy in western countries. Standard treatments include …

The article provides information on diagnosis and management of chronic lymphocytic
leukemia (CLL). It informs about diagnosis of the CLL which includes lymphocyte …

Purpose Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic
lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response …

Purpose: To determine tolerability and for the first time explore efficacy of bendamustine–
rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using two different …

Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently
approved to treat patients with B-cell malignancies, including Waldenström …

Recently, encouraging results in terms of safety and efficacy have been obtained using
bendamustine–rituximab (BR) in untreated chronic lymphocytic leukaemia (CLL) patients …

Introduction Chronic lymphocytic leukemia (CLL) is one of the most common types of
leukemia in adult patients. The landscape of CLL therapy has changed in the last decades …

The objective of this study was to evaluate the safety and efficacy of different lenalidomide
starting doses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). CLL …

Bendamustine and bendamustine/rituximab combinations have shown high efficacy in
relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent B-cell malignancies …